Edesa Biotech Dirección

Dirección controles de criterios 4/4

El CEO de Edesa Biotech es Par Nijhawan , nombrado en Jun 2019, tiene una permanencia de 5.42 años. compensación anual total es $549.56K, compuesta por 62.1% salario y 37.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 14.75% de las acciones de la empresa, por valor de $1.06M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 5.4 años, respectivamente.

Información clave

Par Nijhawan

Chief Executive Officer (CEO)

US$549.6k

Compensación total

Porcentaje del salario del CEO	62.1%
Permanencia del CEO	5.4yrs
Participación del CEO	14.7%
Permanencia media de la dirección	5.4yrs
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Par Nijhawan en comparación con los beneficios de Edesa Biotech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	n/a	n/a	-US$8m
Sep 30 2023	US$550k	US$341k	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	n/a	n/a	-US$16m
Sep 30 2022	US$602k	US$326k	-US$18m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	n/a	n/a	-US$15m
Sep 30 2021	US$1m	US$315k	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	n/a	n/a	-US$8m
Sep 30 2020	US$411k	US$300k	-US$6m
Jun 30 2020	n/a	n/a	-US$5m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	n/a	n/a	-US$4m
Sep 30 2019	US$165k	US$105k	-US$3m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	-US$2m
Dec 31 2018	US$61k	US$27k	-US$2m

Compensación vs. Mercado: La compensación total ($USD549.56K) de Par está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD646.00K).

Compensación vs. Ingresos: La compensación de Par ha sido consistente con los resultados de la empresa en el último año.

CEO

Par Nijhawan (53 yo)

5.4yrs

Permanencia

US$549,561

Compensación

Dr. Pardeep Nijhawan, also known as Par, M.D., FRCPC, AGAF serves as Chief Executive Officer, Company secretary and Director at Edesa Biotech, Inc. since June 7, 2019 and having previously founded and led...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pardeep Nijhawan	CEO, Company Secretary & Director	5.4yrs	US$549.56k	14.75% $ 1.1m
Michael Brooks	President	5.4yrs	US$488.76k	0.13% $ 9.6k
Stephen Lemieux	Chief Financial Officer	1.3yrs	US$463.17k	0.18% $ 12.7k

5.4yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de EDSA es experimentado (5.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pardeep Nijhawan	CEO, Company Secretary & Director	5.4yrs	US$549.56k	14.75% $ 1.1m
Joan Chypyha	Independent Director	1.5yrs	US$30.81k	0.00089% $ 63.9
Sean MacDonald	Independent Director	5.4yrs	US$68.01k	0.063% $ 4.5k
Charles Olson	Independent Director	1.5yrs	US$28.13k	0.081% $ 5.8k
Frank Oakes	Independent Director	14.6yrs	US$56.37k	0.36% $ 25.8k
Patrick Marshall	Independent Director	1.5yrs	US$29.20k	0.014% $ 1.0k
Carlo Sistilli	Independent Chairman of the Board	5.4yrs	US$67.83k	0.016% $ 1.2k

5.4yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de EDSA se considera experimentada (5.4 años de antigüedad promedio).

Edesa Biotech Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Edesa Biotech, Inc., Annual General Meeting, May 30, 2024

Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023

Less than half of directors are independent

Insufficient new directors

High number of new and inexperienced directors

Edesa Biotech, Inc., Annual General Meeting, May 18, 2022

Recent updates

New major risk - Market cap size

Edesa Biotech, Inc. announced that it expects to receive $5.136066 million in funding from Pardeep Nijhawan Medicine Professional Corporation

Edesa Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $3.87 million.

Edesa Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $3.87 million.

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech, Inc., Annual General Meeting, May 30, 2024

Price target decreased by 35% to US$24.00

Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech’S ARDS Drug

Price target decreased by 10% to US$52.33

Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government

New major risk - Market cap size

New minor risk - Share price stability

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023

Edesa Biotech Receives Non-Compliance Notice From Nasdaq

Less than half of directors are independent

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech, Inc. Reports Topline Phase 2B Results for Dermatology Drug

Fda Grants Fast Track to Edesa Biotech's Ards Drug Candidate

No longer forecast to breakeven

Insufficient new directors

Edesa Biotech, Inc. announced that it has received CAD 3.027754 million in funding

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech, Inc. Reports Phase 2b Study Reaches Full Enrollment

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

No longer forecast to breakeven

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Edesa Biotech, Inc. Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

Price target decreased to US$16.33

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

High number of new and inexperienced directors

No longer forecast to breakeven

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa Biotech, Inc., Annual General Meeting, May 18, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to Its Board of Directors

Edesa Biotech, Inc. Announces Peter Van Der Velden Resign from Board and Its Committees

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Edesa Biotech, Inc. Announces Positive Phase 2 Data of Monoclonal Antibody in Hospitalized Covid-19 Patients

Edesa Biotech, Inc. Provides Update on Phase 2/3 Clinical Study Evaluating its Monoclonal Antibody Candidate as Single-Dose Therapy for Hospitalized COVID-19 Patients

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech, Inc. Extends Dermatitis Study to Canada

Edesa Biotech, Inc. Completes Independent Data and Safety Monitoring Board Interim Review of COVID-19 Drug Candidate

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Edesa Biotech, Inc. Completes Enrollment of More Than 50% of the Patients Planned for the Phase 2 Portion of Its Ongoing Phase 2/Phase 3 Clinical Study

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

Edesa Biotech, Inc., Annual General Meeting, Apr 22, 2021

Price target raised to US$17.00

Director recently sold US$58k worth of stock

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Earnings beat expectations, revenue disappoints

Edesa Biotech receives C$14M for COVID-19 study

New 90-day high: US$7.48

New 90-day low: US$4.25

New 90-day low: US$4.63

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Full year 2020 earnings released: US$0.74 loss per share

Revenue and earnings beat expectations

Edesa Biotech EPS misses by $0.04, beats on revenue

New 90-day low: US$5.40

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment